Medigene AG reports on Annual General Meeting 2019

Martinsried/Munich – Medigene AG (FSE: MDG1, Prime Standard), a clinical stage immuno-oncology company focusing on the development of T cell immunotherapies, reports on the Company’s Annual General Meeting which was held in Munich today.

The Executive Management Board of the Company informed the Medigene shareholders about the progress and results of the 2018 fiscal year and about major events in the first months of 2019, including the start of patient treatment in the Phase I/II clinical trial of Medigene’s TCR-T therapy MDG1011, progress in the TCR partnership with bluebird bio, the completion of an additional cell therapy partnership with Roivant/Cytovant as well as positive interim results from the ongoing Phase I/II clinical trial with Medigene’s DC vaccine.

Medigene also announced today that the Company has selected its HA-1-specific TCR as Medigene’s next clinical TCR-T therapy candidate, MDG1021, scheduled to start clinical development in cooperation with the Leiden University Medical Center (LUMC) in 2020.

In addition, Medigene announced today regulatory approval of an amendment to the trial design of its ongoing Phase I/II trial with its TCR-T therapy MDG1011, which is expected to further accelerate patient recruitment together with the increase in clinical trial sites. This amendment broadens the AML patient population potentially eligible for the trial by allowing patients with relapse after allogeneic hematopoietic stem cell transplantation to participate in the trial. In addition, an earlier leukapheresis procedure will be allowed, if patients are positive for the HLA and PRAME criteria and might become trial candidates in the near future.

The presentation of the Annual General Meeting (in German language) and Medigene’s updated corporate presentation (in English language) can be found at Medigene’s website at .

Medigene also announces that the Annual General Meeting of Medigene AG has approved all resolutions of the Company by a large majority:
– Discharge of the Executive Management Board and Supervisory Board
– Election of Ernst & Young as auditor and group auditor for 2019
– Creation of a new Authorized Capital 2019/I with the option to exclude subscription rights
– Elections to the Supervisory Board: Dr. Horst Domdey, Antoinette Hiebeler-Hasner, Dr. Yita Lee, Dr. Keith Manchester, Dr. Frank Mathias, Ronald Scott, Dr. Gerd Zettlmeissl

The Executive Management Board and Supervisory Board of the Company would like to thank the shareholders of Medigene AG for their confidence.

Medigene AG (FSE: MDG1, ISIN DE000A1X3W00, Prime Standard) is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany. The company is developing highly innovative immunotherapies to target various forms and stages of cancer. Medigene concentrates on the development of personalized T cell-based therapies with the focus on T cell-receptor modified T cells (TCR-Ts) and has associated projects currently in pre-clinical and clinical development. For more information, please visit

This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® is a registered trademark of Medigene AG. This trademark may be owned or licensed in select locations only.

Contact Medigene AG
Julia Hofmann, Dr. Robert Mayer
Tel.: +49 – 89 – 20 00 33 – 33 01,

This site is registered on as a development site.